Tenofovir alafenamide hemifumarate
| CAS No. | 1392275-56-7 | Cat. No. | BCP24104 |
| Name | Tenofovir alafenamide hemifumarate | ||
| Synonyms | GS-7340 hemifumarate;GS7340 hemifumarate ;GS 7340 hemifumarate; | ||
| Formula | C46H62N12O14P2 | M. Wt | 1069.02 |
| Description | Tenofovir alafenamide hemifumarate is a nucleotide reverse transcriptase inhibitor (NRTIs) and a novel prodrug of tenofovir. By blocking reverse transcriptase, TAF prevent HIV from multiplying and can reduce the amount of HIV in the body. Tenofovir alafenamide is a prodrug, which means that it is an inactive drug. In the body, tenofovir alafenamide is converted to tenofovir diphosphate (TFV-DP). Tenofovir alafenamide fumarate was approved in November 2015 for treatment of HIV-1. | ||
| Pathways | Microbiology/Virology | ||
| Targets | Reverse Transcriptase HBV HIV | ||
Structure
Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.
For product details of different batches, please contact our Customer
- Service & Tech Support:orders@biochempartner.com
- Website:www.biochempartner.com
Products are for research use only and not for human use. We do not sell to patients.